AstraZeneca

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell AstraZeneca and other ETFs, options, and stocks.

About AZN

AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology. 

CEO
Pascal Soriot
CEOPascal Soriot
Employees
96,100
Employees96,100
Headquarters
Cambridge, Cambridgeshire
HeadquartersCambridge, Cambridgeshire
Founded
1913
Founded1913
Employees
96,100
Employees96,100

AZN Key Statistics

Market cap
243.72B
Market cap243.72B
Price-Earnings ratio
23.22
Price-Earnings ratio23.22
Dividend yield
2.00%
Dividend yield2.00%
Average volume
5.54M
Average volume5.54M
High today
$157.26
High today$157.26
Low today
$155.78
Low today$155.78
Open price
$156.22
Open price$156.22
Volume
1.89M
Volume1.89M
52 Week high
$212.71
52 Week high$212.71
52 Week low
$145.79
52 Week low$145.79

Stock Snapshot

As of today, AstraZeneca(AZN) shares are valued at $156.22. The company's market cap stands at 243.72B, with a P/E ratio of 23.22 and a dividend yield of 2.00%.

On 2026-08-17, AstraZeneca(AZN) stock moved within a range of $155.78 to $157.26. With shares now at $156.22, the stock is trading +0.3% above its intraday low and -0.7% below the session's peak.

Trading activity shows a volume of 1.89M, compared to an average daily volume of 5.54M.

Over the past 52 weeks, AstraZeneca(AZN) stock has traded between a high of $212.71 and a low of $145.79.

Over the past 52 weeks, AstraZeneca(AZN) stock has traded between a high of $212.71 and a low of $145.79.

AZN News

TipRanks 4h
AstraZeneca to discontinue eVOLVE-Lung02 Phase III trial

AstraZeneca (AZN) announced that it is discontinuing the eVOLVE-Lung02 Phase III trial evaluating volrustomig in combination with chemotherapy as a 1st-line the...

TipRanks 6h
AstraZeneca announces results from Phase III trial of Tagrisso, savolitinib

Positive high-level results from the Saffron Phase III trial showed Tagrisso plus savolitinib demonstrated a statistically significant and clinically meaningful...

TipRanks 8h
AstraZeneca: Volrustomig Setback Offset by Oncology Pipeline Strength; Buy Rating and 16,500 GBp Price Target Maintained

In a report released today, Sachin Jain from Bank of America Securities maintained a Buy rating on AstraZeneca, with a price target of p16,500.00. Unlock power...

Analyst ratings

87%

of 30 ratings
Buy
86.7%
Hold
10%
Sell
3.3%

More AZN News

Bloomberg 10h
AstraZeneca Stops Cancer Drug Trial in Setback - Bloomberg.com

...

AstraZeneca Stops Cancer Drug Trial in Setback - Bloomberg.com
TipRanks 11h
AstraZeneca’s Enhertu tops standard care in first-line HER2-mutant lung cancer trial

Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions Subscribe to TipRanks Smart Investor Newsletter, and...

Nasdaq 2d
Are Mega-Mergers Back?

In this episode of Motley Fool Hidden Gems Investing, Motley Fool contributors Travis Hoium, Lou Whiteman, and Rachel Warren discuss: AstraZeneca + BMS? Why m...

Are Mega-Mergers Back?
Nasdaq 4d
Is the Reported $400 Billion AstraZeneca-Bristol Myers Squibb Megamerger a Slam Dunk -- or a Disaster Waiting to Happen?

Key Points Earlier this month, AstraZeneca and Bristol Myers Squibb became the subject of merger rumors. Investors reacted negatively to the rumors, even if o...

Is the Reported $400 Billion AstraZeneca-Bristol Myers Squibb Megamerger a Slam Dunk -- or a Disaster Waiting to Happen?
TipRanks 4d
AstraZeneca’s STEP Asthma Trial Completion: What It Could Mean for AZN Investors

AstraZeneca ($~AZN) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter, more confident...

TipRanks 5d
AstraZeneca Targets Indian Lung Cancer Market With New Imfinzi Safety Study

AstraZeneca plc (GB:AZN) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter, more confi...

TipRanks 5d
CSPC Receives US$30 Million Upfront Payment from AstraZeneca for siRNA Collaboration

Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions Subscribe to TipRanks Smart Investor Newsletter, and...

People also own

Based on the portfolios of people who own AZN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.